Illustration of a hybrid vascular graft integrated into the circulatory system.

Dialysis Access Innovation: How Hybrid Grafts Offer New Hope for Patients with Limited Options

Soraya Malik monogram
Soraya Malik in Health & Wellness October 2026 • 4 min read.

"A closer look at how polytetrafluoroethylene hybrid vascular grafts with preloaded nitinol stents are improving outcomes for hemodialysis patients with complex venous challenges."


Patients with end-stage renal disease (ESRD) often require hemodialysis, a procedure that necessitates reliable vascular access for blood purification. Creating and maintaining this access can be challenging, especially when patients have limited venous outflow or complex anatomical issues. Traditionally, arteriovenous fistulas (AVFs) using a patient's own veins are preferred, but many individuals eventually need arteriovenous grafts (AVGs) as their venous anatomy becomes depleted.

AVGs, while effective, are prone to complications such as stenotic lesions—narrowing of the blood vessels—particularly at the point where the graft connects to the vein. These stenoses can lead to thrombosis (clotting) and make future access more difficult to create. The development of stenotic lesions is often triggered by endothelial injury from shear stress and turbulent blood flow, resulting in neointimal hyperplasia, an excessive growth of cells in the vessel wall.

To combat these challenges, innovative solutions have emerged, such as the Gore hybrid vascular graft. This graft combines a polytetrafluoroethylene (PTFE) graft with a nitinol stent incorporated into the venous outflow end. The stent-graft is designed to be deployed within the outflow vein in a sutureless, straight configuration, aiming to reduce turbulent flow and subsequent neointimal hyperplasia. A recent study has evaluated the clinical outcomes, patency, and complications associated with this hybrid vascular graft in hemodialysis access.

AI Search Multiple angles on this topic

Dialysis Access and Patient Impact

Dialysis access is an important part of treatment for people whose kidneys can no longer adequately remove waste and excess fluid. Patients with limited access options may face more complex treatment decisions and ongoing clinical challenges. The scale and specific impact of these challenges vary among individuals, so broad conclusions should be made cautiously.

How Dialysis Works

Kidney dialysis removes excess water, solutes, and toxins from the blood when the kidneys can no longer perform these functions naturally. Hemodialysis uses a semipermeable membrane to separate blood from dialyzing fluid, while dialysis more broadly filters waste and fluid from the blood. Along with kidney transplantation, dialysis is a form of renal replacement therapy, but it may be needed repeatedly and does not restore normal kidney function.

The Clinical Dialysis Infrastructure

A historical perspective on dialysis also includes the development of organized, Medicare-certified treatment facilities. The DaVita Redlands Dialysis facility in Redlands, California, is described as providing Medicare-certified dialysis care, quality ratings, patient outcomes, and comprehensive kidney care services. This example illustrates how dialysis evolved beyond an isolated procedure into a structured system of ongoing kidney care.

What are the benefits of Hybrid Vascular Grafts for Dialysis Access?

Illustration of a hybrid vascular graft integrated into the circulatory system.

A retrospective study conducted at two academic centers between July 2013 and December 2016 examined the outcomes of patients who underwent surgical AVG creation using the Gore hybrid vascular graft. The study focused on patients with limited venous outflow or challenging anatomy, assessing graft patency, function, and the need for subsequent percutaneous interventions. Forty-six patients were included, with a mean age of 63 ± 13 years; 30 were females (65.2%) and 16 were males (34.8%).

The most common reasons for using a hybrid vascular graft were limited surgical accessibility and/or revision of existing AVGs due to severe stenotic lesions at the venous outflow, accounting for 72% of cases. The study revealed the following patency rates:

  • One-year primary unassisted patency: 44 ± 8%
  • One-year primary assisted patency: 54 ± 8%
  • One-year secondary patency: 66 ± 8%
AI Search Multiple angles on this topic

Research Remains Evolving

Research on dialysis access innovation continues to evolve, particularly for patients who have exhausted conventional options. Early findings and emerging approaches should be interpreted carefully because available evidence may not yet establish long-term benefits for every patient. Ongoing clinical evaluation is needed to clarify durability, safety, and practical usefulness.

Limits and Uncertainty

Hybrid grafts may offer possibilities for difficult access cases, but no access strategy can be assumed to work equally well for every patient. Complications, failure, and the need for additional procedures remain important considerations in dialysis access decisions. Patients and clinicians must weigh potential benefits against uncertainties and individual risks.

Comparing Access Options

Comparing dialysis access approaches requires attention to more than technical design. Clinicians may consider a patient's remaining vessels, treatment needs, prior procedures, and the expected durability of each option. Because these factors differ substantially, the most suitable approach is likely to be individualized rather than universally preferred.

To maintain graft function and patency, approximately one percutaneous intervention per graft was needed each year. These interventions were comparable to those required for traditional AVGs, suggesting that the hybrid graft offers a viable alternative without increasing the intervention burden. Access created with the hybrid vascular graft in a brachial-axillary configuration—connecting the brachial artery to the axillary vein—is an acceptable option for patients with limited venous outflow reserve and challenging anatomy.

The Future of Hemodialysis Access

The findings from this study indicate that hybrid vascular grafts offer a promising solution for hemodialysis patients with limited venous outflow and challenging anatomy. By providing comparable patency rates and intervention needs to traditional AVGs, these grafts expand the options available to clinicians and improve the quality of life for patients undergoing hemodialysis. As research continues, further refinements in graft technology and surgical techniques may lead to even better outcomes, ensuring reliable and durable vascular access for all patients in need.

AI Search Multiple angles on this topic

Balancing Innovation and Evidence

Hybrid grafts represent an effort to expand dialysis access choices for patients with limited conventional options. Their value should be judged by how reliably they support treatment while addressing the practical needs of individual patients. Expert assessment remains important because innovation must be balanced with evidence, safety, and long-term usability.

The Next Stage of Access Innovation

The future of dialysis access may involve more tailored solutions for patients whose standard pathways are no longer available. Further progress will depend on continued evaluation of device performance, patient selection, and long-term outcomes. New approaches may be promising, but their place in routine care will become clearer only as evidence develops.

Access Within the Care System

Dialysis access innovation takes place within a broader healthcare system that must provide procedures, follow-up, supplies, and ongoing treatment. Availability of specialized expertise and coordinated care can influence whether a technically promising option is practical for a patient. These systemic factors mean that access solutions must be considered alongside the realities of delivering long-term kidney care.

Patients Behind the Procedure

For patients with limited access options, a new graft can represent more than a technical intervention. Reliable access may affect the ability to receive continuing dialysis and reduce uncertainty surrounding future treatment. Decisions should therefore account for patient preferences, daily circumstances, and the burdens associated with repeated procedures and ongoing care.

Stent-graft results against their comparators

  • 28In a separate comparison of treatment-area patency at six months, the reported rates were 51% with a stent graft and 23% with balloon angioplasty, a 28-percentage-point difference.[1]

What the comparisons suggest about treating stenosis

These comparisons concern treatment of existing graft outflow stenosis, not a direct test of the hybrid graft used to create dialysis access. They suggest that a stent-based approach can outperform balloon angioplasty on the reported patency measures, but do not establish that the hybrid graft itself produces the same result.[1] [2]

The evidence is relevant to a site where recurrent narrowing is a recognized concern, but it addresses a treatment choice after stenosis rather than prevention of stenosis during access creation.[1] [2]

How the hybrid graft evidence fits with other access reports

The hybrid-graft review covered surgical access creation in a brachial-artery-to-axillary configuration at two academic centers; limited surgical access or revision for severe venous-outflow narrowing accounted for 33 cases.[3]

Other reports describe covered stents as having the strongest supporting evidence for graft outflow stenosis, while balloon angioplasty may be followed by recoil and renewed narrowing. These reports concern treatment of a failing graft, so they provide context rather than a direct comparison of access-creation devices.[1] [2]

What remains uncertain about hybrid graft use

  • What long-term performance and appropriate role will the device have among people dependent on chronic dialysis? Existing reports explicitly call for longer follow-up and broader clinical experience.[4] [5]

Sources

  1. Stent graft versus balloon angioplasty for failing dialysis-access grafts. (www.nejm.org)
  2. UK Kidney Association Clinical Practice Guideline on vascular access for haemodialysis (pmc.ncbi.nlm.nih.gov)
  3. Outcomes of a Polytetrafluoroethylene Hybrid Vascular Graft with Preloaded Nitinol Stent at the Venous Outflow for Dialysis Vascular Access. (doi.org, 2019)
  4. Early Experience With a Novel Hybrid Vascular Graft for Hemodialysis Access Creation in Patients With Disadvantaged Anatomy. (pubmed.ncbi.nlm.nih.gov)
  5. Initial clinical experience with a polytetrafluoroethylene vascular dialysis graft reinforced with nitinol at the venous end. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1016/j.avsg.2018.06.029, Alternate LINK

Title: Outcomes Of A Polytetrafluoroethylene Hybrid Vascular Graft With Preloaded Nitinol Stent At The Venous Outflow For Dialysis Vascular Access

Subject: Cardiology and Cardiovascular Medicine

Journal: Annals of Vascular Surgery

Publisher: Elsevier BV

Authors: Peiman Habibollahi, Mark P. Mantell, Trish Rosenberry, David B. Leeser, Timothy W.I. Clark

Published: 2019-02-01

Everything You Need To Know

1

What are hybrid vascular grafts and how do they help hemodialysis patients?

Hybrid vascular grafts, particularly those using polytetrafluoroethylene (PTFE) combined with a nitinol stent, offer several benefits for hemodialysis access. They are designed to address challenges associated with limited venous outflow and complex anatomical issues. The stent-graft aims to reduce turbulent blood flow and subsequent neointimal hyperplasia, a major cause of graft failure. This can improve patency rates, meaning the graft remains open and functional for a longer period. For patients, this means fewer interventions to maintain access and an improved quality of life. The hybrid grafts provide an alternative when creating arteriovenous fistulas (AVFs) is not feasible.

2

Why are stenotic lesions a problem with arteriovenous grafts, and how do hybrid grafts address this issue?

Arteriovenous grafts (AVGs) are prone to stenotic lesions, which are narrowings in the blood vessels, particularly where the graft connects to the vein. These stenoses can lead to thrombosis, or clotting, making future access more difficult. Stenotic lesions are often caused by endothelial injury from shear stress and turbulent blood flow, resulting in neointimal hyperplasia. The development of stenotic lesions is a common cause of AVG failure, which is why innovations like the Gore hybrid vascular graft are important. This graft is designed to reduce turbulence and subsequent neointimal hyperplasia, which helps maintain graft patency.

3

What do you mean by 'patency rates' when talking about vascular access grafts?

Patency rates refer to how long a vascular access graft remains open and functional without significant intervention. There are different types of patency rates: primary unassisted patency (how long the graft works without any procedures to maintain it), primary assisted patency (how long the graft works with interventions like angioplasty), and secondary patency (how long the graft can be salvaged and made functional again with more extensive interventions). Higher patency rates mean fewer interventions, reduced complications, and better long-term outcomes for hemodialysis patients. In the study, the one-year primary unassisted patency was 44 ± 8%, the one-year primary assisted patency was 54 ± 8%, and the one-year secondary patency was 66 ± 8%.

4

What are percutaneous interventions and why are they relevant to dialysis access?

Percutaneous interventions are minimally invasive procedures performed to maintain the function and patency of vascular access grafts. These interventions often involve angioplasty, where a balloon is used to widen narrowed sections of the graft caused by stenotic lesions. The frequency of these interventions is an important factor in evaluating the success of a particular type of graft. While the hybrid vascular graft requires approximately one percutaneous intervention per graft per year, this rate is comparable to traditional AVGs, indicating that the hybrid graft offers a viable alternative without increasing the intervention burden. This is significant because fewer interventions translate to a better quality of life for hemodialysis patients.

5

What does it mean when a hybrid vascular graft is placed in a 'brachial-axillary configuration'?

A brachial-axillary configuration involves connecting the brachial artery to the axillary vein using a vascular access graft. This approach is particularly useful for patients with limited venous outflow reserve and challenging anatomy, where creating access in other locations may not be feasible. Using the hybrid vascular graft in a brachial-axillary configuration can provide a reliable and durable vascular access option for these patients, ensuring they can receive the hemodialysis treatments they need. This configuration expands the possibilities for patients who might otherwise have limited options.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.